GlassScriptPhysician profile
Justin Bogwu
NPI 1245550656
$7,051.99
in general payments reported to CMS, 2019-2025
34 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $831 · 2021: $788 · 2022: $498 · 2023: $1,200 · 2024: $1,602 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,113.23 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,193.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $701.45 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $650.19 | 2020-2025 | |
| Abbvie INC. | $425.24 | 2021-2025 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $276.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $217.96 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $194.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $176.87 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $156.87 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $103.38 | 2019-2023 | |
| Cranial Technologies, INC | $72.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.50 | 2022-2025 | Xifaxan, Trulance |
| Allergan, INC. | $66.12 | 2020 | |
| Sanofi-Aventis U.S. LLC | $61.65 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $50.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $45.57 | 2021 | |
| Gilead Sciences, INC. | $45.56 | 2019-2025 | |
| Merit Medical Systems INC | $44.00 | 2025 | Esophyx |
| Hologic Sales and Service, LLC | $42.46 | 2022-2023 | Aptima |
| Dexcom, INC. | $41.76 | 2024-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $36.52 | 2020 | |
| Phadia US INC. | $36.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.71 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $31.26 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.55 | 2021 | |
| Dynavax Technologies Corporation | $26.19 | 2024 | Heplisav-B |
| Sanofi Pasteur INC. | $21.98 | 2023 | |
| Neos Therapeutics, LP | $21.24 | 2019 | |
| Shield Therapeutics INC | $16.42 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $14.62 | 2024 | Nuzyra |
| Mylan Specialty L.P. | $12.18 | 2019 | |
| Eisai INC. | $12.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Bogwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.